Altered differentiation and activation of T-cell subsets occur in patients with chronic kidney disease (CKD), but the impact on graft rejection and protective immunity during transplantation are not fully understood.
INTRODUCTION
Chronic kidney disease (CKD) is life-long condition resulting in premature death because of the systemic complications that arise with the progressive loss of kidney function. Patients with end-stage renal disease (ESRD), at the extreme end of the CKD spectrum, have long been recognized to have signs of immune dysfunction evidenced by increased susceptibility to infections [1, 2] , increased risk of cancer [1, 3] , and impaired response to vaccination [4, 5] . It has become increasingly recognized that CKD results in impaired interaction between the innate and adaptive arms of the immune system [6] . ESRD is widely considered to be a chronic state of oxidative stress [7] and inflammation which likely contributes to these alterations.
Alterations in T cells during ESRD may have implications for kidney transplant outcome. It has long been appreciated that prolonged wait time on dialysis is associated with increasing risk of deathcensored renal allograft loss [8, 9] . There is also evidence to suggest that increasing time on dialysis promotes accumulation of alloreactive T cells and the frequency of donor-reactivity on enzyme-linked immunospot (ELISPOT) is strongly correlated with early acute rejection following kidney transplant [10, 11] . Recent studies are beginning to provide new insight into the impact of specific T-cell alterations on renal transplant outcomes. However, much remains to be understood in order to translate this knowledge into clinical practice for personalization of immunosuppression treatment to maximize allograft survival while minimizing consequences of excessive immunosuppression.
With advancements in multiparameter flow cytometry, there have been a number of studies describing differences in specific T-cell phenotypes among patients with CKD and ESRD. The potential for reversibility of these changes with improved renal function and reduced inflammation following kidney transplant [12] are starting to be explored. The full impact of these immune system disturbances on kidney transplant outcomes and on protective immunity during transplantation, however, are not fully understood.
LYMPHOPENIA AND LOSS OF NAÏVE T CELLS
T-cell lymphopenia during renal failure has been appreciated for some time [13] . Data suggest that the global T-cell lymphopenia is primarily because of selective loss of circulating naïve CD4 þ and CD8 þ T cells [14, 15] (Fig. 1) and central memory CD4
þ T cells attributed to increased activation-induced apoptosis [8, 14, 16] and possibly decreased circulating interleukin 7 (IL-7) [15] . The number of naïve and central memory cells significantly correlates with serum urea, creatinine, and phosphorus levels indicating worsening T-cell lymphopenia with increasing severity of renal dysfunction [14] . Furthermore, the dialysis procedure itself appears to exacerbate activation-induced apoptosis [14, 16] and reduces proliferative capacity [17] of T cells.
Thymic output, as measured by the frequency of CD31 þ T cells (recent thymic emigrants) and detection of T-cell receptor (TCR) excision circles (TRECs), is also impaired in dialysis patients compared with similar-aged healthy individuals [18] . Remaining naïve T cells have higher frequency expression of the IL-2 receptor (CD25), the activation marker, CD69 [16] , and inflammatory chemokine receptors, CXCR3 and CCR5 [15] , suggesting an aberrant state of activation. Taken together, ESRD is associated with a T-cell lymphopenia resulting from markedly reduced numbers of naïve cells likely because of a combination of cell loss via activation-induced apoptosis, reduced IL-7 homeostatic signals, and impaired thymic output. Remaining T cells appear to have an aberrant activation status.
It is becoming clear that despite restoration of kidney function and therefore decreased oxidative stress/inflammation [12] , many of the T-cell populations are not normalized following kidney transplantation. A recent prospective, longitudinal study from The Netherlands suggests that naïve T-cell counts and thymic output do not improve following kidney transplantation [19 & ]. However, interpretation of these findings is confounded by the use of immunosuppression following transplantation. For example, recent evidence suggests that induction therapy with antithymoglobulin (ATG) may impair thymic output up to 12 months
KEY POINTS
Patients with renal failure have signs of immune dysfunction with increased risk for infection, cancer, and impaired vaccine response.
The composition of T-cell memory subsets and activation status are altered during chronic kidney disease and in many cases appear to mimic immunologic changes associated with aging.
Patients with CKD exhibit variable accumulation of memory T-cell subsets and CD28 null T cells.
More data are needed describing longitudinal changes in T-cell subset frequencies and function during the entire spectrum of CKD and following transplant, the mechanisms underlying these.
Future studies should be aimed at understanding whether uremia-induced changes in T-cell function are reversible, how they affect transplant outcomes, and the mechanisms underlying these disturbances. 
ACCUMULATION OF EFFECTOR MEMORY SUBSETS
There is growing interest in identifying and understanding the role of preformed, allogenic cross-reactive memory cells in mediating transplant rejection. ESRD patients display increased frequency of circulating effector memory T cells (TEM), particularly of CD8 þ T EMRA cells which are negative for CD45RA and CCR7, in excess of that expected from normal aging [15, 18] . We have also recently reported that children with CKD display similar skewing of T-cell memory subsets [ ]. These patients were also more likely to have long-term allograft dysfunction a median of 6 years following TCR typing, raising the possibility that terminally differentiated cells can contribute to chronic rejection.
DEFINING ALLOAGGRESSIVE T CELLS IN THE CONTEXT OF CHRONIC KIDNEY DISEASE: LOSS OF CD28 AND EXPRESSION OF CD57
The frequency of total memory cells alone is unlikely to be sufficient to predict the risk of transplant rejection or to help personalize immunosuppression regimens. Additional markers within terminally differentiated memory subsets of patients with ESRD have promise for improved prediction of rejection and long-term graft function. One marker of increasing interest is the loss of CD28 given its role in the costimulation pathways targeted by the latest immunosuppressive medication approved for kidney transplant, belatacept.
Several studies have described accumulation of CD4 (Fig. 1) . These cells expressed high levels of perforin, granzyme B, and T-bet. This
þ T cells to secrete TNFa and IFNg in vitro. Patients in this study underwent T-cell phenotyping on average 6 years posttransplant during stable graft function, raising the question whether pretransplant frequencies of these populations may also predict long-term graft dysfunction or possible chronic rejection.
Effector memory cells, which accumulate in patients with renal failure, appear to be inherently resistant to costimulation blockade (e.g., belatacept 
ALTERATIONS IN REGULATORY AND TH17 T CELLS DURING CHRONIC KIDNEY DISEASE
In addition to the observed increase in frequency and activation status of memory T cells, CKD has been shown to be associated with alterations in both T helper 17 (Th17) and regulatory T-cell populations (Fig. 1) . These two CD4 þ T-cell subsets possess distinct functions (Th17 are inflammatory whereas Treg are suppressive), but seminal studies have revealed that their differentiation pathways are related: the presence of TGF-beta alone results in Treg polarization, whereas TGF-beta in the presence of IL-6 results in Th17 polarization. Further, Treg and Th17 cells are capable of transdifferentiating into one another. Intriguingly, in one study patients with CKD/ESRD were shown to have decreased CD4 All of these studies, however, were limited by the fact that they did not include FOXP3 as a marker of Treg populations and by the fact that they were small, single center studies that used different staining definitions to identify Treg populations. More recently, however, a multicenter study in Europe performed a longitudinal analysis of Treg populations in 75 kidney transplant recipients found decreased absolute number and relative frequencies of both natural Tregs
Patients experiencing acute rejection within the first year of transplant (n ¼ 6) had higher pretransplant frequency of activated regulatory T cells. Though a limited sample size, this study raises interesting questions about Treg subset frequencies in the prediction of posttransplant outcomes that deserves further investigation.
In contrast to the generally observed decrease in FOXP3 þ Treg in CKD patients, most studies have observed that CKD results in an increase in Th17 cells. Specifically, one study noted an increase in IL-17-secreting CD4 þ effector memory T cells in patients with ESRD [39] . A separate study noted increased Th17 differentiation in chronic hemodialysis CKD patients, and interestingly noted that this increase in Th17 frequency correlated with higher phosphate and iPTH levels [40] , suggesting that the presence of these metabolites during CKD may promote Th17 differentiation in these patients.
MECHANISMS BY WHICH CHRONIC KIDNEY DISEASE INDUCE IMMUNOLOGIC DERANGEMENTS
The mechanisms by which CKD results in altered differentiation and activation status of many T-cell subsets is poorly understood. One hypothesis is that alterations in the vitamin D/Ca 2þ /phosphorous axis directly impacts T-cell differentiation [41] (Fig. 2) . Evidence that exists to support this idea include the fact that the number of naïve T cells significantly correlated with phosphorus levels, indicating worsening T-cell lymphopenia with increasing severity of hyperparathyroidism [14] , though no direct relationship with parathyroid hormone (PTH) has been born out, and the fact that vitamin D deficiency at time of kidney transplant was an independent risk factor for acute cellular rejection in series of 351 adult kidney transplant recipients [42] . A separate, nonmutually exclusive hypothesis to explain the altered immunity in CKD patients is centered on the role of erythropoietin on the immune system (Fig. 2) . Recent studies have revealed that, compellingly, erythropoietin receptor signaling inhibits human T-cell proliferation and cytokine secretion and decreased allogeneic CD4 þ T-cell proliferation during in-vitro MLR in a dosedependent manner [45 & ]. In a separate analysis, erythropoietin-induced T-cell suppression was found to function indirectly through its effect on macrophages [46 & ]. Because erythropoietin (EPO) levels are significantly decreased during CKD, this could result in dysregulated immune responses to infections and a transplanted organ. In support of this hypothesis, an open-label, multicenter, randomized controlled trial of epoetin-beta treatment in transplant recipients with anemia (Hgb <11.5), demonstrated improved death-censored graft survival and graft function for those patients treated for normalization of anemia (Hgb >13) [47] .
CONCLUSION
In summary, CKD is associated with decreasing naïve T-cell populations with an aberrant state of activation, accumulation of terminally differentiated memory cells some which have lost the expression of CD28 or gained CD57, and an imbalance between suppressive regulatory T cells in and T helper 17 cells (Fig. 1) . With improving recognition that certain T-cell populations present prior to transplant impart increased risk for allograft rejection or dysfunction, one area that needs further exploration is to understand mechanisms underlying accumulation of these populations during CKD and to develop therapeutic approaches to mitigate this risk. In addition, further research is needed to understand how the aforementioned cell populations mediate rejection under various immunosuppressive regimens. In an ideal world, comprehensive immune-phenotyping prior to transplant can identify an individual's optimal regimen to prevent rejection and subsequent monitoring can identify patients at risk for complications (rejection, infection, and cancer) prior to being symptomatic. In order to develop these prognostic tools and personalized immunotherapy, we must first better understand the mechanisms by which a patient's preexisting immune disturbances break through immunosuppression to reject an allograft. Although studies of human biology can identify novel targets via correlation, confirming causation in animal models using young, naïve animals without organ failure are unlikely to recapitulate the critical components of the human condition pretransplant and posttransplant. To date, there is little use of animal models of organ failure in transplant immunology research. We posit that the use of CKD mouse models will illuminate new pathways and targets to better control alloimmunity in CKD patients following transplantation. 
